Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127170661 | 12717066 | 1 | I | 20160830 | 20160906 | 20160906 | EXP | IE-MYLANLABS-2016M1037254 | MYLAN | STORAN ER, O^GORMAN SM, MARKHAM T. GENERALIZED PUSTULAR PSORIASIS TREATED WITH USTEKINUMAB. CLIN-EXP-DERMATOL 2016;41(6):689-690. | 0.00 | Y | 0.00000 | 20160903 | OT | IE | IE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127170661 | 12717066 | 1 | PS | ACITRETIN. | ACITRETIN | 1 | Unknown | 30MG | U | 202148 | |||||||||
| 127170661 | 12717066 | 2 | SS | NEORAL | CYCLOSPORINE | 1 | Unknown | 2.5 MG/KG | U | 0 | |||||||||
| 127170661 | 12717066 | 3 | C | METHOTREXATE. | METHOTREXATE | 1 | Unknown | 2.5 MG/WEEK; LATER INCREASED TO 10 MG/WEEK | U | 0 | |||||||||
| 127170661 | 12717066 | 4 | C | METHOTREXATE. | METHOTREXATE | 1 | Unknown | 10 MG/WEEK; LATER INCREASED TO 20 MG/WEEK | U | 0 | |||||||||
| 127170661 | 12717066 | 5 | C | METHOTREXATE. | METHOTREXATE | 1 | Unknown | 20 MG/WEEK | U | 0 | |||||||||
| 127170661 | 12717066 | 6 | C | FOLINIC ACID | LEUCOVORIN | 1 | Unknown | U | U | 0 | |||||||||
| 127170661 | 12717066 | 7 | C | ADALIMUMAB | ADALIMUMAB | 1 | Unknown | 40 MG/WEEK | U | 0 | |||||||||
| 127170661 | 12717066 | 8 | C | USTEKINUMAB | USTEKINUMAB | 1 | Unknown | 45 MG EVERY 12 WEEKS | U | U | 0 | ||||||||
| 127170661 | 12717066 | 9 | C | USTEKINUMAB | USTEKINUMAB | 1 | Unknown | LOADING DOSE OF 45MG | U | U | 0 | ||||||||
| 127170661 | 12717066 | 10 | C | USTEKINUMAB | USTEKINUMAB | 1 | Unknown | 45MG AT 1ST MONTH | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127170661 | 12717066 | 1 | Pustular psoriasis |
| 127170661 | 12717066 | 2 | Pustular psoriasis |
| 127170661 | 12717066 | 3 | Pustular psoriasis |
| 127170661 | 12717066 | 7 | Pustular psoriasis |
| 127170661 | 12717066 | 8 | Pustular psoriasis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127170661 | 12717066 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127170661 | 12717066 | Acute kidney injury | |
| 127170661 | 12717066 | Hepatic function abnormal | |
| 127170661 | 12717066 | Nausea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127170661 | 12717066 | 7 | 201102 | 0 | ||
| 127170661 | 12717066 | 8 | 201102 | 0 | ||
| 127170661 | 12717066 | 9 | 201102 | 0 | ||
| 127170661 | 12717066 | 10 | 201102 | 0 |